ESMO Virtual Advanced Course on EGFR-Mutated NSCLC 2021

Learning objectives

• Understanding the biology of EGFR in normal and malignant cells
• Gaining insights in the spectrum of EGFR activating mutations, platforms, and strategies for molecular testing
• Understanding the role of biomarkers in selecting NSCLC patients for EGFR TKIs
• Discussing state-of-the-art therapeutic strategies and clinical research in EGFR mutated NSCLC
• Managing toxicity and how to use EGFR TKIs in specific subgroups of patients

Download the programme

Accreditation

The programme of this virtual event has been accredited with 9 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

• Pasi A. Jänne, United States
• Tony S. K. Mok, Hong Kong
• Solange Peters, Switzerland